130 related articles for article (PubMed ID: 20492756)
1. CCAAT/enhancer-binding protein alpha (CEBPA) polymorphisms and mutations in healthy individuals and in patients with peripheral artery disease, ischaemic heart disease and hyperlipidaemia.
Fuchs O; Kostecka A; Provazníková D; Krásná B; Kotlín R; Stanková M; Kobylka P; Dostálová G; Zeman M; Chochola M
Folia Biol (Praha); 2010; 56(2):51-7. PubMed ID: 20492756
[TBL] [Abstract][Full Text] [Related]
2. Nature of frequent deletions in CEBPA.
Fuchs O; Kostecka A; Provaznikova D; Krasna B; Brezinova J; Filkukova J; Kotlin R; Kouba M; Kobylka P; Neuwirtova R; Jonasova A; Caniga M; Schwarz J; Markova J; Maaloufova J; Sponerova D; Novakova L; Cermak J
Blood Cells Mol Dis; 2009; 43(3):260-3. PubMed ID: 19651529
[TBL] [Abstract][Full Text] [Related]
3. Novel mutations in CEBPA in Korean Patients with acute myeloid leukemia with a normal karyotype.
Kim S; Kim DH; Jang JH; Jung CW; Jang MA; Ki CS; Kim JW; Kim SH; Kim HJ
Ann Lab Med; 2012 Mar; 32(2):153-7. PubMed ID: 22389883
[TBL] [Abstract][Full Text] [Related]
4. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.
Lin LI; Chen CY; Lin DT; Tsay W; Tang JL; Yeh YC; Shen HL; Su FH; Yao M; Huang SY; Tien HF
Clin Cancer Res; 2005 Feb; 11(4):1372-9. PubMed ID: 15746035
[TBL] [Abstract][Full Text] [Related]
5. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
Pabst T; Mueller BU; Zhang P; Radomska HS; Narravula S; Schnittger S; Behre G; Hiddemann W; Tenen DG
Nat Genet; 2001 Mar; 27(3):263-70. PubMed ID: 11242107
[TBL] [Abstract][Full Text] [Related]
6. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Zimmermann M; Peeters JK; Valk PJ; Balgobind BV; Sonneveld E; Kaspers GJ; de Bont ES; Trka J; Baruchel A; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
Haematologica; 2011 Mar; 96(3):384-92. PubMed ID: 21134981
[TBL] [Abstract][Full Text] [Related]
7. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.
Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; Meijer J; van Oosterhoud S; van Putten WL; Valk PJ; Berna Beverloo H; Tenen DG; Löwenberg B; Delwel R
Hematol J; 2003; 4(1):31-40. PubMed ID: 12692518
[TBL] [Abstract][Full Text] [Related]
8. CCAAT/enhancer binding protein-alpha polymorphisms occur more frequently than mutations in acute myeloid leukemia and exist across all cytogenetic risk groups and leukemia subtypes.
Leecharendkeat A; Tocharoentanaphol C; Auewarakul CU
Int J Cancer; 2008 Nov; 123(10):2321-6. PubMed ID: 18729193
[TBL] [Abstract][Full Text] [Related]
9. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2.
Snaddon J; Smith ML; Neat M; Cambal-Parrales M; Dixon-McIver A; Arch R; Amess JA; Rohatiner AZ; Lister TA; Fitzgibbon J
Genes Chromosomes Cancer; 2003 May; 37(1):72-8. PubMed ID: 12661007
[TBL] [Abstract][Full Text] [Related]
10. Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia.
Benthaus T; Schneider F; Mellert G; Zellmeier E; Schneider S; Kakadia PM; Hiddemann W; Bohlander SK; Feuring-Buske M; Braess J; Spiekermann K; Dufour A
Br J Haematol; 2008 Oct; 143(2):230-9. PubMed ID: 18752591
[TBL] [Abstract][Full Text] [Related]
11. CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma.
Fuchs O; Provaznikova D; Kocova M; Kostecka A; Cvekova P; Neuwirtova R; Kobylka P; Cermak J; Brezinova J; Schwarz J; Markova J; Salaj P; Klamova H; Maaloufova J; Lemez P; Novakova L; Benesova K
Blood Cells Mol Dis; 2008; 40(3):401-5. PubMed ID: 18182175
[TBL] [Abstract][Full Text] [Related]
12. Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia.
Fuster O; Barragán E; Bolufer P; Such E; Valencia A; Ibáñez M; Dolz S; de Juan I; Jiménez A; Gómez MT; Buño I; Martínez J; Cervera J; Montesinos P; Moscardó F; Sanz MÁ
Ann Hematol; 2012 Jan; 91(1):1-7. PubMed ID: 21538063
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias.
Gombart AF; Hofmann WK; Kawano S; Takeuchi S; Krug U; Kwok SH; Larsen RJ; Asou H; Miller CW; Hoelzer D; Koeffler HP
Blood; 2002 Feb; 99(4):1332-40. PubMed ID: 11830484
[TBL] [Abstract][Full Text] [Related]
14. Detection of CEBPA double mutants in acute myeloid leukemia using a custom gene expression array.
van Vliet MH; Burgmer P; de Quartel L; Brand JP; de Best LC; Viëtor H; Löwenberg B; Valk PJ; van Beers EH
Genet Test Mol Biomarkers; 2013 May; 17(5):395-400. PubMed ID: 23485358
[TBL] [Abstract][Full Text] [Related]
15.
Mannelli F; Ponziani V; Bencini S; Bonetti MI; Benelli M; Cutini I; Gianfaldoni G; Scappini B; Pancani F; Piccini M; Rondelli T; Caporale R; Gelli AM; Peruzzi B; Chiarini M; Borlenghi E; Spinelli O; Giupponi D; Zanghì P; Bassan R; Rambaldi A; Rossi G; Bosi A
Haematologica; 2017 Mar; 102(3):529-540. PubMed ID: 28250006
[TBL] [Abstract][Full Text] [Related]
16. The +37 kb Cebpa Enhancer Is Critical for Cebpa Myeloid Gene Expression and Contains Functional Sites that Bind SCL, GATA2, C/EBPα, PU.1, and Additional Ets Factors.
Cooper S; Guo H; Friedman AD
PLoS One; 2015; 10(5):e0126385. PubMed ID: 25938608
[TBL] [Abstract][Full Text] [Related]
17. Characterization of CEBPA Mutations and Polymorphisms and their Prognostic Relevance in De Novo Acute Myeloid Leukemia Patients.
Sarojam S; Raveendran S; Vijay S; Sreedharan J; Narayanan G; Sreedharan H
Asian Pac J Cancer Prev; 2015; 16(9):3785-92. PubMed ID: 25987038
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
19. Capillary gel electrophoresis: a simple method for identification of mutations and polymorphisms in the CEBPA gene in patients with acute myeloid leukaemia.
Juhl-Christensen C; Bomberg M; Melsvik D; Hokland P; Nyvold CG
Eur J Haematol; 2008 Oct; 81(4):273-80. PubMed ID: 18616509
[TBL] [Abstract][Full Text] [Related]
20. Infrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia.
Chim CS; Wong AS; Kwong YL
Br J Haematol; 2002 Dec; 119(4):988-90. PubMed ID: 12472578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]